Addex Therapeutics grants director 943K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. director Isaac Manke received 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share. The options vest in equal monthly installments over four years beginning at the exercisable date. Each option grants the right to purchase one ADXN share listed on SIX Swiss Exchange, and the options expire November 10, 2036. The reported post-grant stock-option position was tied to 992,854 underlying shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 942,854 | $0.00 | $0.00 |
Footnotes (2)
- F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Key Figures
Key Terms
vest on equal monthly installments financial
exercisable date financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did ADXN director Isaac Manke receive, and what was the exercise price?
When do Isaac Manke’s ADXN options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.